An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, Lisa A., Anderson, Evan J., Rouphael, Nadine G., Roberts, Paul C., Makhene, Mamodikoe, Coler, Rhea N., McCullough, Michele P., Chappell, James D., Denison, Mark R., Stevens, Laura J., Pruijssers, Andrea J., McDermott, Adrian, Flach, Britta, Doria-Rose, Nicole A., Corbett, Kizzmekia S., Morabito, Kaitlyn M., O’Dell, Sijy, Schmidt, Stephen D., Swanson, Phillip A., Padilla, Marcelino, Mascola, John R., Neuzil, Kathleen M., Bennett, Hamilton, Sun, Wellington, Peters, Etza, Makowski, Mat, Albert, Jim, Cross, Kaitlyn, Buchanan, Wendy, Pikaart-Tautges, Rhonda, Ledgerwood, Julie E., Graham, Barney S., Beigel, John H.·2020·New England Journal of Medicine
DOI 10.1056/nejmoa2022483

Cited by (3,231)

Items 401–500 of 3,231

  1. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
    Per Johan Klasse, Douglas F. Nixon, John P. Moore · 2021 · Science Advances
  2. Vaccines - safety in pregnancy
    Mala Arora, Rama Lakshmi · 2021 · Best Practice & Research Clinical Obstetrics & Gynaecology
  3. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
    Madeleine F. Jennewein, Anna J. MacCamy, Nicholas R. Akins, Junli Feng, Leah J. Homad, Nicholas K. Hurlburt, Emilie Seydoux, Yu-Hsin Wan, Andrew B. Stuart, Venkata Viswanadh Edara et al. · 2021 · Cell Reports
  4. Forensic and Pharmaceutical Risks in the Organization of Pharmacotherapy of Covid, Post-Covid and Long-Covid Disorders. COVID-19 and Vaccination Practice Standards.
    Вікторія Шаповалова · 2022 · SSP Modern Pharmacy and Medicine
  5. A review of criteria strictness in “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”
    Amai, Motoki, Nojima, Masanori, Yuki, Yoshikazu, Kiyono, Hiroshi, Nagamura, Fumitaka · 2023 · Vaccine
  6. The potential neurological effect of the COVID‐19 vaccines: A review
    Lu Lu, Weixi Xiong, Jie Mu, Qi Zhang, Hesheng Zhang, Ling Zou, Weimin Li, Li He, Josemir W. A. S. Sander, Dong Zhou · 2021 · Acta Neurologica Scandinavica
  7. Discovery and Characterization of Spike N‐Terminal Domain‐Binding Aptamers for Rapid SARS‐CoV‐2 Detection
    Nataly A. Kacherovsky, Lucy F. Yang, Ha V. Dang, Emmeline L. Cheng, Ian I. Cardle, Alexandra C. Walls, Matthew McCallum, Drew L. Sellers, Frank DiMaio, Stephen J. Salipante et al. · 2021 · Angewandte Chemie International Edition
  8. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
    Gili Regev‐Yochay, Yaniv Lustig, Gili Joseph, Mayan Gilboa, Noam Barda, Ilana Gens, Victoria Indenbaum, Osnat Halpern, Shiri Katz-Likvornik, Tal Levin et al. · 2023 · The Lancet Microbe
  9. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates
    Eric M. Mucker, Alec W. Freyn, Sandra L. Bixler, Deniz Cizmeci, Caroline G. Atyeo, Patricia L. Earl, Harini Natarajan, Genesis Santos, Tiffany R. Frey, Rafael H. Levin et al. · 2024 · Cell
  10. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2
    Rajat Kumar Mudgal, Sanketkumar Nehul, Shailly Tomar · 2020 · Human Vaccines & Immunotherapeutics
  11. Development of vaccines and antivirals for combating viral pandemics
    Norbert Pardi, Drew Weissman · 2020 · Nature Biomedical Engineering
  12. AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire
    Phillip A. Swanson, Marcelino Padilla, Wesley Hoyland, Kelly McGlinchey, Paul Fields, Sagida Bibi, Saul N. Faust, Adrian B. McDermott, Teresa Lambe, Andrew John Pollard et al. · 2021 · Science Translational Medicine
  13. Current Developments and Challenges of mRNA Vaccines
    Jinjin Chen, Jianzhu Chen, Qiaobing Xu · 2022 · Annual Review of Biomedical Engineering
  14. A COVID-19 Vaccine: Big Strides Come with Big Challenges
    Juanita Mellet, Michael Sean Pepper · 2021 · Vaccines
  15. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
    Coyle, Peter V., Chemaitelly, Hiam, Ben Hadj Kacem, Mohamed Ali, Abdulla Al Molawi, Naema Hassan, El Kahlout, Reham Awni, Gilliani, Imtiaz, Younes, Nourah, Al Anssari, Ghada Ali A.A., Al Kanaani, Zaina, Al Khal, Abdullatif et al. · 2021 · iScience
  16. Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo
    Almanza-Reyes, Horacio, Moreno, Sandra, Plascencia-López, Ismael, Alvarado-Vera, Martha, Patrón-Romero, Leslie, Borrego, Belén, Reyes-Escamilla, Alberto, Valencia-Manzo, Daniel, Brun, Alejandro, Pestryakov, Alexey et al. · 2021 · PLOS ONE
  17. An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
    Kailash C. Petkar, Suyash M. Patil, Sandip S. Chavhan, Kan Kaneko, Krutika Khanderao Sawant, Nitesh K. Kunda, Imran Y. Saleem · 2021 · Pharmaceutics
  18. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
    Lindsey Elizabeth Roeker, David A. Knorr, Melissa S. Pessin, Lakshmi V. Ramanathan, Meghan C. Thompson, Lori Ann Leslie, Andrew David Zelenetz, Anthony R. Mato · 2020 · Leukemia
  19. The immunology of SARS-CoV-2 infections and vaccines
    Lilit Grigoryan, Bali Pulendran · 2020 · Seminars in Immunology
  20. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles
    Uri Elia, Srinivas Ramishetti, Ronit Rosenfeld, Niels Dammes, Erez Bar‐Haim, Gonna Somu Naidu, Efi Makdasi, Yfat Yahalom-Ronen, Hadas Tamir, Nir Paran et al. · 2021 · ACS Nano
  21. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
    Yael Peled, Eilon Ram, Ii Jacob Lavee I, Amit Segev, Shlomi Matezky, Anat Wieder-Finesod, Rebecca Halperin, Michal Mandelboim, Victoria Indenbaum, Itzchak Levy et al. · 2021 · The Journal of Heart and Lung Transplantation
  22. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
    Alexandra Tauzin, Shang Yu Gong, Guillaume Beaudoin-Bussières, Dani Vézina, Romain Gasser, Lauriane Nault, Lorie Marchitto, Mehdi Benlarbi, Debashree Chatterjee, Manon Nayrac et al. · 2021 · Cell Host & Microbe
  23. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations
    Janet Sultana, Giampiero Mazzaglia, Nicoletta Luxi, Antonino Cancellieri, Annalisa Capuano, Carmen Ferrajolo, Chiara de Waure, Guido Ferlazzo, Gianluca Trifirò · 2020 · Expert Review of Vaccines
  24. COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
    Juan García‐Arriaza, Urtzi Garaigorta, Patricia Pérez, Adrián Lázaro-Frías, Carmen Zamora, Pablo Gastaminza, Carlos del Fresno, José M. Casasnovas, Carlos Óscar S. Sorzano, David Sancho et al. · 2021 · Journal of Virology
  25. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
    Kizzmekia S. Corbett, Matthew Gagné, Danielle A. Wagner, Sarah O’ Connell, Sandeep Narpala, Dillon R. Flebbe, Shayne F. Andrew, Rachel L. Davis, Barbara J. Flynn, Timothy S. Johnston et al. · 2021 · Science
  26. Lipid-Based Drug Delivery Systems for Diseases Managements
    Douweh Leyla Gbian, Abdelwahab Omri · 2022 · Biomedicines
  27. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19
    Saman Yasamineh, Hesam Ghafouri Kalajahi, Pooneh Yasamineh, Yalda Yazdani, Omid Gholizadeh, Raheleh Tabatabaie, Hamed Afkhami, Fatemeh Davodabadi, Alireza Khanalipour farkhad, Daryoush Pahlevan et al. · 2022 · Journal of Nanobiotechnology
  28. Nanocarrier vaccines for SARS-CoV-2
    Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, Mai Mohamed Abdelmoaty, Jacob D. Cohen, Preet Amol Singh, Ashish Baldi, Neha Bajwa, Raj Kumar et al. · 2021 · Advanced Drug Delivery Reviews
  29. T lymphocytes as critical mediators in tissue regeneration, fibrosis, and the foreign body response
    Kenneth M. Adusei, Tran B. Ngo, Kaitlyn Sadtler · 2020 · Acta Biomaterialia
  30. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
    Jialu Zhang, Qian He, Chaoqiang An, Qunying Mao, Fan Gao, Lianlian Bian, Wu Xing, Qian Wang, Pei Liu, Lifang Song et al. · 2021 · Emerging Microbes & Infections
  31. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
    Marta Alenquer, Filipe Ferreira, Diana Lousa, Mariana Valério, Mónica Medina-Lopes, Marie‐Louise Bergman, Juliana Gonçalves, Jocelyne Demengeot, Ricardo B. Leite, Jingtao Lilue et al. · 2021 · PLoS Pathogens
  32. Role of COVID-19 Vaccines in SARS-CoV-2 Variants
    Zhou Zhou, Yimiao Zhu, Ming Chu · 2022 · Frontiers in Immunology
  33. Advances in gene-based vaccine platforms to address the COVID-19 pandemic
    Deborah Pushparajah, Salma Jimenez, Shirley Lau Wong, Hibah Alattas, Nafiseh Nafissi, Roderick Adrian Slavcev · 2021 · Advanced Drug Delivery Reviews
  34. RNA-based therapies: A cog in the wheel of lung cancer defense
    Parvez Κhan, Jawed Akhtar Siddiqui, Imayavaramban Lakshmanan, Apar Kishor Ganti, Ravi Salgia, Maneesh Jain, Surinder K. Batra, Mohd Wasim Nasser · 2021 · Molecular Cancer
  35. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients
    Sabina Herrera, Jordi Colmenero, Mariona Pascal, Miguel Escobedo, M. Castel, Eduard Solé‐González, Eduard Palou, Natalia Egri, Pablo Ruíz, Mar Mosquera et al. · 2021 · American Journal of Transplantation
  36. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery
    Jilian R. Melamed, Khalid A. Hajj, Namit Chaudhary, Daria Strelkova, Mariah Lynn Arral, Norbert Pardi, Mohamad‐Gabriel Alameh, Jason B. Miller, Lukas Farbiak, Daniel J. Siegwart et al. · 2021 · Journal of Controlled Release
  37. T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems
    Yalong Yang, Fei Yang, Zhuan-qing Huang, Yuan-yuan Li, Hao-yuan Shi, Qi Sun, Yue Ma, Yao Wang, Ying Zhang, Sen Yang et al. · 2023 · Frontiers in Immunology
  38. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
    Stamatatos, Leonidas, Czartoski, Julie, Wan, Yu-Hsin, Homad, Leah J., Rubin, Vanessa, Glantz, Hayley, Neradilek, Moni, Seydoux, Emilie, Jennewein, Madeleine F., MacCamy, Anna J. et al. · 2021
  39. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
    Crystal Y. Zheng, Indrani Kar, Claire Kaori Chen, Crystal Sau, Sophia Woodson, Alessandro Serra, Hesham Abboud · 2020 · CNS Drugs
  40. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
    Takehiro Ura, Akio Yamashita, Nobuhisa Mizuki, Kenji Okuda, Masaru Shimada · 2020 · Vaccine
  41. Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use
    Mingwang Shen, Jian Zu, Christopher Kincaid Fairley, José A. Pagán, Li An, Zhanwei Du, Yuming Guo, Libin Rong, Yanni Xiao, Guihua Zhuang et al. · 2021 · Vaccine
  42. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
    Jeremijenko, Andrew, Chemaitelly, Hiam, Ayoub, Houssein H., Alishaq, Moza, Abou-Samra, Abdul-Badi, Al Ajmi, Jameela Ali A.A., Al Ansari, Nasser Ali Asad, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas et al. · 2021 · Emerging Infectious Diseases
  43. COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines
    Ishan Garg, Rahul Shekhar, Abu Baker Sheikh, Suman Pal · 2021 · Infectious Disease Reports
  44. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
    Xingyue An, Melisa A. Martinez-Paniagua, Ali Rezvan, Samiur Rahman Sefat, Mohsen Fathi, Shailbala Singh, Sujit Biswas, Melissa Pourpak, Cassian Yee, Xinli Liu et al. · 2021 · iScience
  45. Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles
    Anna Piperno, Maria Teresa Sciortino, Elena Giusto, Monica Montesi, Silvia Panseri, Angela Scala · 2021 · International Journal of Nanomedicine
  46. Stabilized coronavirus spike stem elicits a broadly protective antibody
    Ching‐Lin Hsieh, Anne P. Werner, Sarah R. Leist, Laura J. Stevens, Ester Falconer, Jory A. Goldsmith, Chia‐Wei Chou, Olubukola M. Abiona, Ande West, Kathryn Westendorf et al. · 2021 · Cell Reports
  47. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
    Katie L. Flanagan, Emma Best, Nigel W. Crawford, Michelle Giles, Archana Koirala, Kristine K. Macartney, Fiona Mary Russell, Benjamin W. Teh, Sophie Chien-Hui Wen · 2020 · Frontiers in Immunology
  48. Vaccinology in the post−COVID-19 era
    Rino Rappuoli, Ennio De Gregorio, Giuseppe Del Giudice, Sanjay Kumar Phogat, Simone Pecetta, Mariagrazia Pizza, Emmanuel Hanon · 2021 · Proceedings of the National Academy of Sciences
  49. SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
    Jeroen B. K. Pollet, Wen‐Hsiang Chen, Leroy Versteeg, Brian P. Keegan, Bin Zhan, Junfei Wei, Zhuyun Liu, Jungsoon Lee, Rahki Kundu, Rakesh Adhikari et al. · 2021 · Human Vaccines & Immunotherapeutics
  50. Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine—Specific Cancer Targeting with Undetectable Toxicity
    Daniel W. Binzel, Xin Li, Nicolas Burns, Eshan Khan, Wen-Jui Lee, Li-Ching Chen, Satheesh Ellipilli, Wayne O. Miles, Yuan Soon Ho, Peixuan Guo · 2021 · Chemical Reviews
  51. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge
    Anthony T. DiPiazza, Sarah R. Leist, Olubukola M. Abiona, Juan I. Moliva, Anne P. Werner, Mahnaz Minai, Bianca M. Nagata, Kevin W. Bock, Emily Phung, Alexandra Schäfer et al. · 2021 · Immunity
  52. COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine
    Naveen L. Pereira, Ferhaan Ahmad, Mirnela Byku, Nathan W. Cummins, Alanna A. Morris, ANJALI TIKU OWENS, Sony Tuteja, Sharon Cresci · 2020 · Mayo Clinic Proceedings
  53. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
    Weina Sun, Stephen McCroskery, Wen‐Chun Liu, Sarah R. Leist, Yonghong Liu, Randy A. Albrecht, Stefan Slamanig, Justine Oliva, Fatima Amanat, Alexandra Schäfer et al. · 2020 · Vaccines
  54. T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
    Vincenzo Marasco, Cristiana Carniti, Anna Guidetti, Lucia Farina, Martina Magni, Rosalba Miceli, Ludovica Calabretta, Paolo Verderio, Silva Ljevar, Fabio Serpenti et al. · 2021 · British Journal of Haematology
  55. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα
    Hadar Edelman-Klapper, Eran Zittan, Ariella Bar‐Gil Shitrit, Keren Masha Rabinowitz, Idan Goren, Irit Avni‐Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran, Henit A. Yanai et al. · 2021 · Gastroenterology
  56. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
    Khadija Khan, Gila Lustig, Cornelius Roemer, Kajal Reedoy, Zesuliwe Jule, Farina Karim, Yashica Ganga, Mallory P. Bernstein, Zainab Baig, Laurelle Jackson et al. · 2023 · Nature Communications
  57. COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
    Ramandeep Singh, Alisha Kang, Xiang‐Qian Luo, Mangalakumari Jeyanathan, Amy E. Gillgrass, Sam Afkhami, Zhou Xing · 2021 · The FASEB Journal
  58. Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy
    Chi Zhang, Yifan Ma, Jingjing Zhang, Jimmy Chun‐Tien Kuo, Zhongkun Zhang, Haotian Xie, Jing Zhu, Tongzheng Liu · 2022 · Molecules
  59. Lipid nanoparticles: Composition, formulation, and application
    Sijia Xu, Zhenzhen Hu, Fenglin Song, Ying Ge Xu, Xuexiang Han · 2025 · Molecular Therapy — Methods & Clinical Development
  60. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk
    Ronen Shavit, Ramit Maoz Segal, Mona Iancovici Kidon, Irena Offengenden, Soad Haj Yahia, Diti Machnes‐Maayan, Yulia Lifshitz, Stanley Niznik, Shirly Frizinsky, Michal Deutch et al. · 2021 · JAMA Network Open
  61. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines
    Parisa Ghasemiyeh, Soliman Mohammadi‐Samani, Negar Firouzabadi, Ali Dehshahri, Afsaneh Vazin · 2021 · International Immunopharmacology
  62. Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena
    Vivek P. Chavda, Md. Mer Mosharraf Hossain, Jayesh Beladiya, Vasso Apostolopoulos · 2021 · Biologics
  63. Multicomponent Synthesis of Imidazole-Based Ionizable Lipids for Highly Efficient and Spleen-Selective Messenger RNA Delivery
    Wang Xu Dong, Zhibin Li, Tailin Hou, Yanqiong Shen, Zixuan Guo, Yi‐Tan Su, Ziqi Chen, Huimin Pan, Wei Jiang, Yucai Wang · 2024 · Journal of the American Chemical Society
  64. The 2020 race towards SARS-CoV-2 specific vaccines
    Tomasz M. M Karpiński, Marcin Ożarowski, Agnieszka Seremak‐Mrozikiewicz, Hubert Wolski, Donald Włodkowic · 2020 · Theranostics
  65. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice
    Wenjun Wang, Baoying Huang, Yanping Zhu, Wenjie Tan, Mingzhao Zhu · 2021 · Cellular and Molecular Immunology
  66. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
    Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, Alexandra Kupke, Georgia Kalodimou, Leonard Limpinsel, Nisreen M.A. Okba, Berislav Bošnjak, Inga Sandrock, Ivan Odak et al. · 2021 · Proceedings of the National Academy of Sciences
  67. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
    Yaling An, Shihua Li, Xiyue Jin, Jian-Bao Han, Kun Xu, Senyu Xu, Yuxuan Han, Chuanyu Liu, Tianyi Zheng, Mei Liu et al. · 2022 · Emerging Microbes & Infections
  68. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
    Meriem Bekliz, Kenneth Adea, Pauline Vetter, Christiane Sigrid Eberhardt, Krisztina Hosszu-Fellous, Diem‐Lan Vu, Olha Puhach, Manel Essaidi-Laziosi, Sophie Waldvogel‐Abramowski, Caroline Stephan et al. · 2022 · Nature Communications
  69. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations
    Stafford, Irene A., Parchem, Jacqueline G., Sibai, Baha M. · 2021 · American Journal of Obstetrics and Gynecology
  70. A roadmap to operationalize and evaluate impact in a learning health system
    Claire Allen, Katie Coleman, Kayne D. Mettert, Cara C. Lewis, Emily O. Westbrook, Paula Lozano · 2021 · Learning Health Systems
  71. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
    Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, Dipankar Das, Narasimha Reddy Molugu, Sai D. Prasad, Srinivas V. Kannappa, Krishna M. Ella, Rajaram Ravikrishnan, Amit Awasthi et al. · 2021 · iScience
  72. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines
    Jiping Liu, Junbang Wang, Jinfang Xu, Han Xia, Yue Wang, Chunxue Zhang, Wei Chen, Huina Zhang, Qi Liu, Rong Zhu et al. · 2021 · Cell Discovery
  73. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
    Hengrui Liu, Sho Iketani, Arie Zask, Nisha Khanizeman, Eva Bednářová, F. Forouhar, Brandon S. Fowler, Seo Jung Hong, Hiroshi Mohri, Manoj S. Nair et al. · 2022 · Nature Communications
  74. Genetically modified organisms: adapting regulatory frameworks for evolving genome editing technologies
    Pablo Rozas, Eduardo I. Kessi‐Pérez, Claudio Martı́nez · 2022 · Biological Research
  75. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
    Chandramani Singh, Savita Verma, Prabhakar Reddy, Michael Diamond, David T. Curiel, Chintan Patel, Manish Kumar Jain, Sagar Vivek Redkar, Amit Suresh Bhate, Vivek Gundappa et al. · 2023 · npj Vaccines
  76. Development of multi-epitope peptide-based vaccines against SARS-CoV-2
    Hui Xuan Lim, Jianhua Lim, Seyed Davoud Jazayeri, Sibrandes Poppema, Chit Laa Poh · 2020 · Biomedical Journal
  77. Preparing the public for COVID-19 vaccines: How can general practitioners build vaccine confidence and optimise uptake for themselves and their patients?
    Margie H Danchin, Ruby Biezen, Jo-Anne Elizabeth Manski-Nankervis, Jessica Kaufman, Julie Leask · 2020 · Australian Journal of General Practice
  78. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
    Saborni Chakraborty, Vamsee V. A. Mallajosyula, Cristina M. Tato, Gene S. Tan, Taia T. Wang · 2021 · Advanced Drug Delivery Reviews
  79. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
    Kevin O. Saunders, Norbert Pardi, Robert Parks, Sampa Santra, Zekun Mu, Laura L. Sutherland, Richard M. Scearce, Maggie Barr, Amanda Eaton, Giovanna E. Hernandez et al. · 2021 · npj Vaccines
  80. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine
    Jana Sophia Buhre, Tamás Pongrácz, Inga Künsting, Anne Sophie Lixenfeld, Wenjun Wang, Jan Nouta, Selina Lehrian, Franziska Schmelter, Hanna B. Lunding, Lara Dühring et al. · 2023 · Frontiers in Immunology
  81. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants
    Timothy S. Johnston, Shuk Hang Li, Mark M. Painter, Reilly K. Atkinson, Naomi R. Douek, David B. Reeg, Daniel C. Douek, E. John Wherry, Scott E. Hensley · 2024 · Immunity
  82. Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
    Anderson, Evan J, Campbell, James D, Creech, C Buddy, Frenck, Robert, Kamidani, Satoshi, Munoz, Flor M, Nachman, Sharon, Spearman, Paul · 2021 · Clinical Infectious Diseases
  83. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
    2021
  84. A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
    Alana Gerhardt, Emily A. Voigt, Michelle C. Archer, Sierra Reed, Elise Larson, Neal Van Hoeven, Ryan M. Kramer, Christopher B. Fox, Corey Casper · 2022 · Molecular Therapy — Methods & Clinical Development
  85. COVID-19 vaccines adverse events: potential molecular mechanisms
    Malamatenia Lamprinou, Athanasios Sachinidis, Εleni Stamoula, Theofanis Vavilis, Georgios Papazisis · 2023 · Immunologic Research
  86. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
    Voigt, Emily A., Gerhardt, Alana, Hanson, Derek, Jennewein, Madeleine F., Battisti, Peter, Reed, Sierra, Singh, Jasneet, Mohamath, Raodoh, Bakken, Julie, Beaver, Samuel et al. · 2022 · npj Vaccines
  87. Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
    Steve Pascolo · 2021 · Viruses
  88. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
    Samuel David Stampfer, Marissa‐Skye Goldwater, Scott Kristian Jew, Sean Elliott Bujarski, Bernard Sean S. Regidor, David Daniely, Haiming Chen, Ning Xu, Mingjie Li, Tracy Green et al. · 2021 · Leukemia
  89. Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
    Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, ARTO A. I. PALMU, Merit M. Melin · 2021 · European Journal of Immunology
  90. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening
    Christoph Gorgulla, Krishna Mohan Das, Kendra E. Leigh, Marco Cespugli, Patrick D. Fischer, Zifu Wang, Guilhem Tesseyre, Shreya Pandita, Alec Shnapir, Anthony Calderaio et al. · 2021 · iScience
  91. COVID-19 mRNA vaccines
    Qingrui Huang, Jiawei Zeng, Jinghua Yan · 2021 · Journal of genetics and genomics/Journal of Genetics and Genomics
  92. Selective and noncovalent targeting of RAS mutants for inhibition and degradation
    Kai Wen Teng, Steven T. Tsai, Takamitsu Hattori, Carmine Fedele, Akiko Koide, Chao Yang, Xuben Hou, Yingkai Zhang, Benjamin G. Neel, John P. O’Bryan et al. · 2021 · Nature Communications
  93. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
    Anusha Nathan, Elizabeth J. Rossin, Clarety Kaseke, Ryan Jin-hyung Park, Ashok Khatri, Dylan Koundakjian, Jonathan M. Urbach, Nishant Kumar Singh, Arman A. Bashirova, Rhoda Tano-Menka et al. · 2021 · Cell
  94. Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults
    Allison August, Christine A. Shaw, Heather Ruth Lee, Conor Knightly, Shiva Kalidindia, Laurence Chu, Brandon J. Essink, William Seger, Tal Z. Zaks, Igor V. Smolenov et al. · 2022 · Open Forum Infectious Diseases
  95. Current State of the First COVID-19 Vaccines
    Birgit M. Prüβ · 2021 · Vaccines
  96. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases
    To Sing Fung, Ding Xiang Liu · 2021 · Annual Review of Microbiology
  97. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
    Ai‐Ming Yu, Mei‐Juan Tu · 2021 · Pharmacology & Therapeutics
  98. Nano toolbox in immune modulation and nanovaccines
    Mohammad Azharuddin, Geyunjian Harry Zhu, Anirban Sengupta, Jorma Hinkula, Nigel K.H. Slater, Hirak Kumar Patra · 2022 · Trends in biotechnology
  99. SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”
    Benjamín L. Sievers, Mark T. K. Cheng, Kata Csiba, Bo Meng, Ravindra K. Gupta · 2023 · Cellular and Molecular Immunology
  100. Together We Make the Difference: National Strategy for Recruitment and Participation in Alzheimer’s and Related Dementias Clinical Research
    Cerise L. Elliott · 2020 · Ethnicity & Disease